Randomized Trialhigh evidence
Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial.
Lancet (London, England)·October 25, 2025·PMID 41077049
Why it mattersThere are no approved pharmacotherapies for OSA, leaving many patients reliant on CPAP or oral appliances. Sultiame’s dose-dependent efficacy on AHI and symptoms suggests a potential oral treatment option, warranting further investigation.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled